🇳🇬 PCN Licensed: LAG20247B39C9 📍 17 Ademola Osinowo Street, Ikosi Ketu, Lagos 📞 +234 705 050 5001 ✉ care@hubpharmafrica.com ⚡ Same-Day Delivery in Lagos 🌍 Serving patients in 35 countries 💊 180,000+ Lives Impacted ✅ NDPC Audit Compliant NDPC/AUDIT/24430 🇳🇬 PCN Licensed: LAG20247B39C9 📍 17 Ademola Osinowo Street, Ikosi Ketu, Lagos 📞 +234 705 050 5001 ✉ care@hubpharmafrica.com ⚡ Same-Day Delivery in Lagos 🌍 Serving patients in 35 countries 💊 180,000+ Lives Impacted ✅ NDPC Audit Compliant NDPC/AUDIT/24430

HomeOnline Pharmacy StoreAll MedicinesMENINGITIS B (BESXERO)

MENINGITIS B (BESXERO)

Sale!

MENINGITIS B (BESXERO)

Original price was: ₦420,000.00.Current price is: ₦390,000.00.

Besxero is a vaccine designed to protect against invasive disease caused by Neisseria meningitidis serogroup B, a major cause of bacterial meningitis and sepsis. The vaccine targets serogroup B of the meningococcus bacteria, which is not covered by other meningococcal vaccines.

Very secured payment methods
Shipping will be calculated on checkout
Please note that price may increase due to exchange rate, ensure updated price before making payment
Categories: , Tag:
Dispensing supervised byPharm. Tope Kareem, B.PharmSuperintendent Pharmacist and Co-founder, HubPharm Africa. Over 13 years in practice.PCN Reg. 023669
Last updated 28 August 2026How we write and check this informationPCN Premises Licence LAG20247B39C9

Description

Besxero is a vaccine designed to protect against invasive disease caused by Neisseria meningitidis serogroup B, a major cause of bacterial meningitis and sepsis. The vaccine targets serogroup B of the meningococcus bacteria, which is not covered by other meningococcal vaccines.

Uses:

  1. Prevention of Meningococcal Disease: Besxero is used to protect against meningococcal disease caused by serogroup B, which can lead to serious infections like meningitis (inflammation of the protective membranes covering the brain and spinal cord) and septicemia (blood poisoning).
  2.  Recommended for Certain Age Groups: It is commonly recommended for adolescents and young adults, particularly those aged 16 to 23 years, who are at increased risk of contracting meningococcal disease. It may also be used in younger children and infants in some cases. 

Reviews

There are no reviews yet.

Be the first to review “MENINGITIS B (BESXERO)”

Your email address will not be published. Required fields are marked *

Hi! I'm Afiya
Chat with me on WhatsApp - I speak Yoruba, Igbo, Hausa, Pidgin & 46 more languages!
Chat with Afiya AI
Talk to a Pharmacist
Get expert medication advice from our licensed pharmacists - available 7 days a week!
Chat with our Pharmacist
Close